Tag #Drug Costs

Showing 1 to 8 of 8 results

forbes.com

🌐 85% Global Worthiness

Aug 13, 22:17

Trump Demands Pharmaceutical Companies Lower Drug Prices

President Trump's 60-day ultimatum to 17 pharmaceutical companies demands proposals for lowering U.S. drug prices to match the lowest prices in developed nations, aiming to correct decades-long pricing imbalances and potentially reforming the entire healthcare ecosystem.

Trump Demands Pharmaceutical Companies Lower Drug Prices

President Trump's 60-day ultimatum to 17 pharmaceutical companies demands proposals for lowering U.S. drug prices to match the lowest prices in developed nations, aiming to correct decades-long pricing imbalances and potentially reforming the entire healthcare ecosystem.

Progress

44% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

What are the immediate consequences of President Trump's 60-day ultimatum to pharmaceutical manufacturers to lower drug prices?

President Trump recently issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding proposals to lower U.S. drug prices to match the lowest prices in other developed countries. This action aims to alleviate the burden on U.S. consumers who currently pay significantly more than their counterparts abroad. The directive could reshape global pharmaceutical pricing, potentially impacting both pharmaceutical profits and foreign healthcare systems.

spanish.china.org.cn

🌐 85% Global Worthiness

Aug 1, 07:15

Trump Demands US Drug Price Cuts from 17 Pharmaceutical Companies

President Trump sent letters to 17 pharmaceutical CEOs on Thursday, demanding a 60-day price reduction on drugs or facing unspecified consequences; this follows a May executive order reinstating a "nation most favored" plan to link US drug prices to lower international rates, and resulted in stock d...

Trump Demands US Drug Price Cuts from 17 Pharmaceutical Companies

President Trump sent letters to 17 pharmaceutical CEOs on Thursday, demanding a 60-day price reduction on drugs or facing unspecified consequences; this follows a May executive order reinstating a "nation most favored" plan to link US drug prices to lower international rates, and resulted in stock d...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What immediate actions did President Trump take to address high drug prices in the US, and what are the potential immediate consequences?

President Trump sent letters to 17 pharmaceutical CEOs, demanding they lower drug prices within 60 days or face unspecified consequences. He cited the significantly higher drug prices in the US compared to other developed nations, referencing a "nation most favored" plan aiming to link US prices to lower international costs. The letters followed a May executive order reinstating this plan.

forbes.com

🌐 85% Global Worthiness

Jul 10, 19:15

PBMs: The Primary Driver of High Drug Prices

The FTC and DOJ listening sessions revealed that Pharmacy Benefit Managers (PBMs), not pharmaceutical companies, are the primary cause of high drug prices due to their anti-competitive practices; the three largest PBMs control 80% of prescriptions, favoring higher-priced drugs and limiting access to...

PBMs: The Primary Driver of High Drug Prices

The FTC and DOJ listening sessions revealed that Pharmacy Benefit Managers (PBMs), not pharmaceutical companies, are the primary cause of high drug prices due to their anti-competitive practices; the three largest PBMs control 80% of prescriptions, favoring higher-priced drugs and limiting access to...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do PBMs' practices hinder the development and market entry of generic and biosimilar drugs?

PBMs' actions stifle competition and innovation, particularly impacting biosimilars. Their rebate structure incentivizes the selection of higher-priced drugs, even when cheaper options exist, resulting in reduced market share for biosimilars and a decline in new biosimilar development. This is further compounded by PBMs' control over formularies and the use of prior authorization and "fail-first" requirements.

nrc.nl

🌐 85% Global Worthiness

Jul 8, 19:20

Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit

A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.

Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit

A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.

Progress

52% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

What long-term consequences might this ruling have on pharmaceutical research and development, investment in new drugs, and global access to essential medicines?

This case could significantly impact pharmaceutical pricing practices globally. A ruling in favor of Farma ter Verantwoording could set a precedent, influencing future pricing negotiations and potentially limiting exorbitant profits from patented drugs. The calculation of 'excessive profit' based on a socially acceptable price might offer a new framework for evaluating pharmaceutical pricing practices, impacting future drug development and accessibility.

lefigaro.fr

🌐 85% Global Worthiness

Aug 1, 01:13

Trump Demands Lower Drug Prices from 17 Pharmaceutical Companies

On Thursday, President Trump sent letters to 17 pharmaceutical companies demanding lower drug prices in the US by September 29th, threatening unspecified action if they don't comply; several companies' stock prices fell in response.

Trump Demands Lower Drug Prices from 17 Pharmaceutical Companies

On Thursday, President Trump sent letters to 17 pharmaceutical companies demanding lower drug prices in the US by September 29th, threatening unspecified action if they don't comply; several companies' stock prices fell in response.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Trump's current approach to lowering drug prices compare to his previous attempts and campaign promises?

Trump's action reflects his past campaign promise to lower drug prices in the US, which are significantly higher than in other developed nations – up to 2.5 times higher than in France, according to a Rand Corporation study. This latest attempt uses direct pressure on companies, rather than legislative action, to achieve price reductions.

cnnespanol.cnn.com

🌐 85% Global Worthiness

Aug 1, 19:16

Trump Demands US Drug Prices Match Lower Global Prices

President Trump is demanding that 17 major US pharmaceutical companies match their US drug prices to the much lower prices offered to patients in other countries within 60 days, threatening unspecified consequences if they don't comply, although experts say this is unlikely to happen.

Trump Demands US Drug Prices Match Lower Global Prices

President Trump is demanding that 17 major US pharmaceutical companies match their US drug prices to the much lower prices offered to patients in other countries within 60 days, threatening unspecified consequences if they don't comply, although experts say this is unlikely to happen.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What immediate actions is President Trump taking to lower prescription drug prices in the US, and what are the potential immediate consequences?

President Trump is demanding that 17 major pharmaceutical companies match US drug prices to significantly lower prices in other countries within 60 days, a move experts deem unlikely to succeed. He sent letters outlining requirements including extending the lowest price paid in a comparable country to all Medicaid drugs and ensuring similar pricing across Medicare, Medicaid, and commercial insurers. This follows a May executive order aiming to reduce US drug prices, which are sometimes more than three times higher than in other developed nations.

telegraaf.nl

🌐 85% Global Worthiness

Jul 9, 16:15

Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate

A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.

Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate

A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the central question raised by the lawsuit against AbbVie concerning the pricing of Humira?

AbbVie earned €2.1 billion from Humira between 2004 and 2018, a drug used to treat rheumatism and other inflammatory diseases. This led to a lawsuit from the Stichting Farma ter Verantwoording, arguing that AbbVie's pricing was excessive and displaced other healthcare needs. The patent on Humira expired in 2018, causing a near 90% price drop by 2023.

us.cnn.com

🌐 85% Global Worthiness

May 12, 22:09

Trump Executive Order Aims to Slash Prescription Drug Prices

President Trump signed an executive order on Monday mandating that drugmakers offer US patients the lowest price paid for a drug in a peer country, threatening consequences such as increased drug importation and FDA actions if manufacturers don't significantly lower prices; this broad measure extend...

Trump Executive Order Aims to Slash Prescription Drug Prices

President Trump signed an executive order on Monday mandating that drugmakers offer US patients the lowest price paid for a drug in a peer country, threatening consequences such as increased drug importation and FDA actions if manufacturers don't significantly lower prices; this broad measure extend...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of President Trump's executive order on prescription drug prices in the US?

President Trump signed an executive order aiming to lower prescription drug prices by forcing drugmakers to offer US patients the lowest price paid in any peer country, a policy known as "Most Favored Nation" pricing. Failure to comply could result in consequences such as increased drug importation and FDA regulatory actions. The order also targets pharmacy benefit managers and seeks to enable direct patient-manufacturer drug purchases.

Showing 1 to 8 of 8 results